TransMedics Group (NASDAQ:TMDX) Given New $109.00 Price Target at Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX) had its target price lowered by Canaccord Genuity Group from $169.00 to $109.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also commented on the stock. Needham & Company LLC lowered their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Oppenheimer lowered their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley increased their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $82.40 on Tuesday. The stock has a market cap of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. The firm has a fifty day moving average price of $140.51 and a 200-day moving average price of $139.29. TransMedics Group has a 1 year low of $38.13 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the company earned ($0.12) earnings per share. The firm’s revenue was up 63.7% on a year-over-year basis. Equities analysts anticipate that TransMedics Group will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock worth $9,518,181 in the last 90 days. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after acquiring an additional 50,673 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after purchasing an additional 30,092 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of TransMedics Group during the second quarter worth $1,400,000. Handelsbanken Fonder AB raised its position in shares of TransMedics Group by 657.6% in the third quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock valued at $10,111,000 after buying an additional 55,900 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of TransMedics Group in the third quarter worth about $2,560,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.